[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fCBP7vWzTnF6dPPF7QQGvGZnXOUJyZlEUy879otDqmMo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":50,"rows":57},"Makerere University",[4],141,false,13,25,235779,6,78,[14,17,20,23,25,27,30,32],{"name":15,"count":16},"HIV",11,{"name":18,"count":19},"HIV Infections",10,{"name":21,"count":22},"Malaria",8,{"name":24,"count":11},"Tuberculosis",{"name":26,"count":11},"HIV\u002FAIDS",{"name":28,"count":29},"PrEP",3,{"name":31,"count":29},"HIV-1-infection",{"name":33,"count":29},"Covid19",[35,40,45],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT06477185","Characterization of Tuberculosis Associated Lung Fibrosis and Respiratory Impairment, and Prevention Using Doxycycline","2026-12-20","Doxycycline",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT03945448","Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia","2027-06","Single dose liposomal Amphotericin and Fluconazole",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05909358","Solidarity\u002FTokomeza Ebola Trial","2027-09","CAd3",[51,52,53,54,55,56],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[58,84,102,137,161,179,197,235,262,280,306,324,342,368,386,413,431,456,474,498,516,541,565,593,611,636,654,680,706,724,769,794,822,840,858,876,900,925,943,970,988,1006,1030,1054,1079,1102,1130,1148,1166,1184,1202,1220,1238,1265,1290,1315,1340,1367,1385,1412,1430,1456,1482,1504,1532,1550,1568,1586,1614,1632,1656,1680,1705,1723,1741,1766,1784,1809,1835,1860,1887,1912,1937,1972,1998,2023,2048,2074,2098,2123,2148,2173,2197,2215,2240],{"intervention":44,"totalTrials":59,"cells":60},1,{"EARLY_PHASE1":61,"PHASE1":64,"PHASE2":66,"PHASE3":68,"PHASE4":80,"NA":82},{"trials":62,"activeCount":63},[],0,{"trials":65,"activeCount":63},[],{"trials":67,"activeCount":63},[],{"trials":69,"activeCount":59,"soonestReadout":43},[70],{"nctId":41,"briefTitle":42,"status":71,"phases":72,"primaryCompletion":43,"completion":73,"start":74,"enrollment":75,"conditions":76,"interventions":78},"RECRUITING",[53,54],"2027-08","2019-06-20",356,[77],"Cryptococcal Meningitis",[44,79],"Fluconazole",{"trials":81,"activeCount":63},[],{"trials":83,"activeCount":63},[],{"intervention":79,"totalTrials":59,"cells":85},{"EARLY_PHASE1":86,"PHASE1":88,"PHASE2":90,"PHASE3":92,"PHASE4":98,"NA":100},{"trials":87,"activeCount":63},[],{"trials":89,"activeCount":63},[],{"trials":91,"activeCount":63},[],{"trials":93,"activeCount":59,"soonestReadout":43},[94],{"nctId":41,"briefTitle":42,"status":71,"phases":95,"primaryCompletion":43,"completion":73,"start":74,"enrollment":75,"conditions":96,"interventions":97},[53,54],[77],[44,79],{"trials":99,"activeCount":63},[],{"trials":101,"activeCount":63},[],{"intervention":39,"totalTrials":103,"cells":104},2,{"EARLY_PHASE1":105,"PHASE1":107,"PHASE2":109,"PHASE3":131,"PHASE4":133,"NA":135},{"trials":106,"activeCount":63},[],{"trials":108,"activeCount":63},[],{"trials":110,"activeCount":59,"soonestReadout":38},[111,119],{"nctId":36,"briefTitle":37,"status":71,"phases":112,"primaryCompletion":38,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":118},[53],"2027-12","2024-12-04",200,[117],"Tuberculosis, Pulmonary",[39],{"nctId":120,"briefTitle":121,"status":122,"phases":123,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":130},"NCT02850913","Doxycycline for the Treatment of Nodding Syndrome","UNKNOWN",[53],"2020-04-05","2020-08-05","2016-09-05",230,[129],"Seizures",[39],{"trials":132,"activeCount":63},[],{"trials":134,"activeCount":63},[],{"trials":136,"activeCount":63},[],{"intervention":49,"totalTrials":59,"cells":138},{"EARLY_PHASE1":139,"PHASE1":141,"PHASE2":143,"PHASE3":155,"PHASE4":157,"NA":159},{"trials":140,"activeCount":63},[],{"trials":142,"activeCount":63},[],{"trials":144,"activeCount":59,"soonestReadout":48},[145],{"nctId":46,"briefTitle":47,"status":146,"phases":147,"primaryCompletion":48,"completion":48,"start":148,"enrollment":149,"conditions":150,"interventions":152},"NOT_YET_RECRUITING",[52,53],"2023-07",2121,[151],"Sudan Ebola Virus Vaccines",[49,153,154],"ChAdox1","rVSV-SUDV",{"trials":156,"activeCount":63},[],{"trials":158,"activeCount":63},[],{"trials":160,"activeCount":63},[],{"intervention":153,"totalTrials":59,"cells":162},{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":173,"PHASE4":175,"NA":177},{"trials":164,"activeCount":63},[],{"trials":166,"activeCount":63},[],{"trials":168,"activeCount":59,"soonestReadout":48},[169],{"nctId":46,"briefTitle":47,"status":146,"phases":170,"primaryCompletion":48,"completion":48,"start":148,"enrollment":149,"conditions":171,"interventions":172},[52,53],[151],[49,153,154],{"trials":174,"activeCount":63},[],{"trials":176,"activeCount":63},[],{"trials":178,"activeCount":63},[],{"intervention":154,"totalTrials":59,"cells":180},{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":191,"PHASE4":193,"NA":195},{"trials":182,"activeCount":63},[],{"trials":184,"activeCount":63},[],{"trials":186,"activeCount":59,"soonestReadout":48},[187],{"nctId":46,"briefTitle":47,"status":146,"phases":188,"primaryCompletion":48,"completion":48,"start":148,"enrollment":149,"conditions":189,"interventions":190},[52,53],[151],[49,153,154],{"trials":192,"activeCount":63},[],{"trials":194,"activeCount":63},[],{"trials":196,"activeCount":63},[],{"intervention":198,"totalTrials":103,"cells":199},"Artemether-lumefantrine",{"EARLY_PHASE1":200,"PHASE1":202,"PHASE2":204,"PHASE3":206,"PHASE4":208,"NA":233},{"trials":201,"activeCount":63},[],{"trials":203,"activeCount":63},[],{"trials":205,"activeCount":63},[],{"trials":207,"activeCount":63},[],{"trials":209,"activeCount":63},[210,221],{"nctId":211,"briefTitle":212,"status":122,"phases":213,"primaryCompletion":214,"completion":215,"start":216,"enrollment":217,"conditions":218,"interventions":220},"NCT04708496","Optimizing Malaria Treatment for HIV-Malaria Co-infected Individuals",[55],"2024-01","2024-03","2021-01-18",888,[219,21],"HIV Coinfection",[198],{"nctId":222,"briefTitle":223,"status":122,"phases":224,"completion":225,"start":226,"enrollment":227,"conditions":228,"interventions":230},"NCT00540202","Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children",[55],"2008-04","2007-09",302,[229],"Uncomplicated Malaria",[231,232],"artemether-lumefantrine","Oral quinine",{"trials":234,"activeCount":63},[],{"intervention":236,"totalTrials":59,"cells":237},"Nevirapine without dose escalation",{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":242,"PHASE3":244,"PHASE4":246,"NA":260},{"trials":239,"activeCount":63},[],{"trials":241,"activeCount":63},[],{"trials":243,"activeCount":63},[],{"trials":245,"activeCount":63},[],{"trials":247,"activeCount":63},[248],{"nctId":249,"briefTitle":250,"status":251,"phases":252,"primaryCompletion":253,"completion":254,"start":255,"enrollment":256,"conditions":257,"interventions":258},"NCT00617643","Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis","COMPLETED",[55],"2009-06","2010-12","2008-05",18,[18,24],[236,259],"Nevirapine initiation with dose escalation",{"trials":261,"activeCount":63},[],{"intervention":259,"totalTrials":59,"cells":263},{"EARLY_PHASE1":264,"PHASE1":266,"PHASE2":268,"PHASE3":270,"PHASE4":272,"NA":278},{"trials":265,"activeCount":63},[],{"trials":267,"activeCount":63},[],{"trials":269,"activeCount":63},[],{"trials":271,"activeCount":63},[],{"trials":273,"activeCount":63},[274],{"nctId":249,"briefTitle":250,"status":251,"phases":275,"primaryCompletion":253,"completion":254,"start":255,"enrollment":256,"conditions":276,"interventions":277},[55],[18,24],[236,259],{"trials":279,"activeCount":63},[],{"intervention":281,"totalTrials":59,"cells":282},"Lumefantrine-artemether and nevirapine",{"EARLY_PHASE1":283,"PHASE1":285,"PHASE2":287,"PHASE3":289,"PHASE4":291,"NA":304},{"trials":284,"activeCount":63},[],{"trials":286,"activeCount":63},[],{"trials":288,"activeCount":63},[],{"trials":290,"activeCount":63},[],{"trials":292,"activeCount":63},[293],{"nctId":294,"briefTitle":295,"status":122,"phases":296,"primaryCompletion":297,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":301},"NCT00620438","Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients",[55],"2011-07","2008-02",90,[18,24],[281,302,303],"lumefantrine-artemether and efavirenz","Lumefantrine-artemether and rifampicin",{"trials":305,"activeCount":63},[],{"intervention":302,"totalTrials":59,"cells":307},{"EARLY_PHASE1":308,"PHASE1":310,"PHASE2":312,"PHASE3":314,"PHASE4":316,"NA":322},{"trials":309,"activeCount":63},[],{"trials":311,"activeCount":63},[],{"trials":313,"activeCount":63},[],{"trials":315,"activeCount":63},[],{"trials":317,"activeCount":63},[318],{"nctId":294,"briefTitle":295,"status":122,"phases":319,"primaryCompletion":297,"completion":297,"start":298,"enrollment":299,"conditions":320,"interventions":321},[55],[18,24],[281,302,303],{"trials":323,"activeCount":63},[],{"intervention":303,"totalTrials":59,"cells":325},{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":332,"PHASE4":334,"NA":340},{"trials":327,"activeCount":63},[],{"trials":329,"activeCount":63},[],{"trials":331,"activeCount":63},[],{"trials":333,"activeCount":63},[],{"trials":335,"activeCount":63},[336],{"nctId":294,"briefTitle":295,"status":122,"phases":337,"primaryCompletion":297,"completion":297,"start":298,"enrollment":299,"conditions":338,"interventions":339},[55],[18,24],[281,302,303],{"trials":341,"activeCount":63},[],{"intervention":343,"totalTrials":59,"cells":344},"Triomune",{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":351,"PHASE4":353,"NA":366},{"trials":346,"activeCount":63},[],{"trials":348,"activeCount":63},[],{"trials":350,"activeCount":63},[],{"trials":352,"activeCount":63},[],{"trials":354,"activeCount":63},[355],{"nctId":356,"briefTitle":357,"status":251,"phases":358,"primaryCompletion":359,"completion":360,"start":361,"enrollment":362,"conditions":363,"interventions":364},"NCT01025830","Triomune Bioequivalence With Innovators",[55],"2006-06","2008-03","2006-02",20,[26],[343,365],"Zerit\u002FEpivir\u002FViramune",{"trials":367,"activeCount":63},[],{"intervention":365,"totalTrials":59,"cells":369},{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":374,"PHASE3":376,"PHASE4":378,"NA":384},{"trials":371,"activeCount":63},[],{"trials":373,"activeCount":63},[],{"trials":375,"activeCount":63},[],{"trials":377,"activeCount":63},[],{"trials":379,"activeCount":63},[380],{"nctId":356,"briefTitle":357,"status":251,"phases":381,"primaryCompletion":359,"completion":360,"start":361,"enrollment":362,"conditions":382,"interventions":383},[55],[26],[343,365],{"trials":385,"activeCount":63},[],{"intervention":387,"totalTrials":59,"cells":388},"caudal bupivacaine",{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":393,"PHASE3":395,"PHASE4":397,"NA":411},{"trials":390,"activeCount":63},[],{"trials":392,"activeCount":63},[],{"trials":394,"activeCount":63},[],{"trials":396,"activeCount":63},[],{"trials":398,"activeCount":63},[399],{"nctId":400,"briefTitle":401,"status":251,"phases":402,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":407,"interventions":409},"NCT02456142","CAUDAL BUPIVACAINE VERSUS INTRAVENOUS MORPHINE ON TIME TO FIRST ANALGESIC REQUIREMENT",[55],"2015-10","2015-12","2015-07",70,[408],"Post Operative Pain",[387,410],"intravenous morphine",{"trials":412,"activeCount":63},[],{"intervention":410,"totalTrials":59,"cells":414},{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":419,"PHASE3":421,"PHASE4":423,"NA":429},{"trials":416,"activeCount":63},[],{"trials":418,"activeCount":63},[],{"trials":420,"activeCount":63},[],{"trials":422,"activeCount":63},[],{"trials":424,"activeCount":63},[425],{"nctId":400,"briefTitle":401,"status":251,"phases":426,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":427,"interventions":428},[55],[408],[387,410],{"trials":430,"activeCount":63},[],{"intervention":432,"totalTrials":59,"cells":433},"Artemether\u002Flumefantrine",{"EARLY_PHASE1":434,"PHASE1":436,"PHASE2":438,"PHASE3":440,"PHASE4":442,"NA":454},{"trials":435,"activeCount":63},[],{"trials":437,"activeCount":63},[],{"trials":439,"activeCount":63},[],{"trials":441,"activeCount":63},[],{"trials":443,"activeCount":63},[444],{"nctId":445,"briefTitle":446,"status":122,"phases":447,"primaryCompletion":448,"completion":448,"start":449,"enrollment":450,"conditions":451,"interventions":452},"NCT05605925","Ivermectin-artemisinin Combination Therapy for Eradication of Malaria",[55],"2022-12-31","2022-08-04",138,[21],[432,453],"Ivermectin",{"trials":455,"activeCount":63},[],{"intervention":453,"totalTrials":59,"cells":457},{"EARLY_PHASE1":458,"PHASE1":460,"PHASE2":462,"PHASE3":464,"PHASE4":466,"NA":472},{"trials":459,"activeCount":63},[],{"trials":461,"activeCount":63},[],{"trials":463,"activeCount":63},[],{"trials":465,"activeCount":63},[],{"trials":467,"activeCount":63},[468],{"nctId":445,"briefTitle":446,"status":122,"phases":469,"primaryCompletion":448,"completion":448,"start":449,"enrollment":450,"conditions":470,"interventions":471},[55],[21],[432,453],{"trials":473,"activeCount":63},[],{"intervention":475,"totalTrials":59,"cells":476},"Lumefantrine - lopinavir\u002Fritonavir drug interaction",{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":483,"PHASE4":485,"NA":496},{"trials":478,"activeCount":63},[],{"trials":480,"activeCount":63},[],{"trials":482,"activeCount":63},[],{"trials":484,"activeCount":63},[],{"trials":486,"activeCount":63},[487],{"nctId":488,"briefTitle":489,"status":251,"phases":490,"primaryCompletion":491,"completion":491,"start":298,"enrollment":492,"conditions":493,"interventions":494},"NCT00619944","Drug Interaction Study Between Lumefantrine and Lopinavir\u002FRitonavir",[55],"2008-12",32,[18],[475,495],"Lumefantrine only arm",{"trials":497,"activeCount":63},[],{"intervention":495,"totalTrials":59,"cells":499},{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":504,"PHASE3":506,"PHASE4":508,"NA":514},{"trials":501,"activeCount":63},[],{"trials":503,"activeCount":63},[],{"trials":505,"activeCount":63},[],{"trials":507,"activeCount":63},[],{"trials":509,"activeCount":63},[510],{"nctId":488,"briefTitle":489,"status":251,"phases":511,"primaryCompletion":491,"completion":491,"start":298,"enrollment":492,"conditions":512,"interventions":513},[55],[18],[475,495],{"trials":515,"activeCount":63},[],{"intervention":517,"totalTrials":59,"cells":518},"Rifampicin, Isoniazid, Ethambutol, Pyrazinamide",{"EARLY_PHASE1":519,"PHASE1":521,"PHASE2":523,"PHASE3":525,"PHASE4":527,"NA":539},{"trials":520,"activeCount":63},[],{"trials":522,"activeCount":63},[],{"trials":524,"activeCount":63},[],{"trials":526,"activeCount":63},[],{"trials":528,"activeCount":63},[529],{"nctId":530,"briefTitle":531,"status":122,"phases":532,"primaryCompletion":533,"completion":533,"start":534,"enrollment":535,"conditions":536,"interventions":538},"NCT01782950","Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes",[55],"2016-03","2013-02",400,[537],"AIDS With Tuberculosis",[517],{"trials":540,"activeCount":63},[],{"intervention":542,"totalTrials":59,"cells":543},"nevirapine, stavudine, lamivudine",{"EARLY_PHASE1":544,"PHASE1":546,"PHASE2":548,"PHASE3":550,"PHASE4":552,"NA":563},{"trials":545,"activeCount":63},[],{"trials":547,"activeCount":63},[],{"trials":549,"activeCount":63},[],{"trials":551,"activeCount":63},[],{"trials":553,"activeCount":63},[554],{"nctId":555,"briefTitle":556,"status":251,"phases":557,"primaryCompletion":558,"completion":559,"start":560,"enrollment":256,"conditions":561,"interventions":562},"NCT00455585","Comparison of Plasma Drug Levels of Triomune 40 With Those of the Originator Products",[55],"2007-05","2007-11","2007-01",[18],[542],{"trials":564,"activeCount":63},[],{"intervention":566,"totalTrials":59,"cells":567},"Low dose ketamine",{"EARLY_PHASE1":568,"PHASE1":570,"PHASE2":572,"PHASE3":574,"PHASE4":576,"NA":591},{"trials":569,"activeCount":63},[],{"trials":571,"activeCount":63},[],{"trials":573,"activeCount":63},[],{"trials":575,"activeCount":63},[],{"trials":577,"activeCount":63},[578],{"nctId":579,"briefTitle":580,"status":251,"phases":581,"primaryCompletion":582,"completion":583,"start":584,"enrollment":585,"conditions":586,"interventions":589},"NCT02434939","Low-dose Ketamine vs Morphine for Vaso-occlusive Crisis in Sicklers",[55],"2016-01","2016-02","2015-06",240,[587,588],"Sickle Cell Crisis","Acute Pain",[566,590],"Morphine",{"trials":592,"activeCount":63},[],{"intervention":590,"totalTrials":59,"cells":594},{"EARLY_PHASE1":595,"PHASE1":597,"PHASE2":599,"PHASE3":601,"PHASE4":603,"NA":609},{"trials":596,"activeCount":63},[],{"trials":598,"activeCount":63},[],{"trials":600,"activeCount":63},[],{"trials":602,"activeCount":63},[],{"trials":604,"activeCount":63},[605],{"nctId":579,"briefTitle":580,"status":251,"phases":606,"primaryCompletion":582,"completion":583,"start":584,"enrollment":585,"conditions":607,"interventions":608},[55],[587,588],[566,590],{"trials":610,"activeCount":63},[],{"intervention":612,"totalTrials":59,"cells":613},"Single dose antibiotic",{"EARLY_PHASE1":614,"PHASE1":616,"PHASE2":618,"PHASE3":620,"PHASE4":622,"NA":634},{"trials":615,"activeCount":63},[],{"trials":617,"activeCount":63},[],{"trials":619,"activeCount":63},[],{"trials":621,"activeCount":63},[],{"trials":623,"activeCount":63},[624],{"nctId":625,"briefTitle":626,"status":251,"phases":627,"primaryCompletion":583,"completion":533,"start":628,"enrollment":629,"conditions":630,"interventions":632},"NCT02736682","Single Dose Ceftriaxone and Metronidazole Versus Multiple Doses for Antibiotic Prophylaxis at Elective Cesarean Section.",[55],"2015-09",174,[631],"Post Operative Infections",[612,633],"Multiple dose antibiotic",{"trials":635,"activeCount":63},[],{"intervention":633,"totalTrials":59,"cells":637},{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":644,"PHASE4":646,"NA":652},{"trials":639,"activeCount":63},[],{"trials":641,"activeCount":63},[],{"trials":643,"activeCount":63},[],{"trials":645,"activeCount":63},[],{"trials":647,"activeCount":63},[648],{"nctId":625,"briefTitle":626,"status":251,"phases":649,"primaryCompletion":583,"completion":533,"start":628,"enrollment":629,"conditions":650,"interventions":651},[55],[631],[612,633],{"trials":653,"activeCount":63},[],{"intervention":655,"totalTrials":59,"cells":656},"Intervention arm: 4% chlorhexidine",{"EARLY_PHASE1":657,"PHASE1":659,"PHASE2":661,"PHASE3":663,"PHASE4":665,"NA":678},{"trials":658,"activeCount":63},[],{"trials":660,"activeCount":63},[],{"trials":662,"activeCount":63},[],{"trials":664,"activeCount":63},[],{"trials":666,"activeCount":63},[667],{"nctId":668,"briefTitle":669,"status":251,"phases":670,"primaryCompletion":671,"completion":671,"start":672,"enrollment":673,"conditions":674,"interventions":677},"NCT02606565","Efficacy of Umbilical Cord Cleansing With a Single Application of 4% Chlorhexidine for the Prevention of Newborn Infections in Uganda: a Randomized Controlled Trial",[55],"2020-10-01","2016-07",4760,[675,676],"Omphalitis","Septicaemia",[655],{"trials":679,"activeCount":63},[],{"intervention":681,"totalTrials":59,"cells":682},"Ketamine",{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":687,"PHASE3":689,"PHASE4":691,"NA":704},{"trials":684,"activeCount":63},[],{"trials":686,"activeCount":63},[],{"trials":688,"activeCount":63},[],{"trials":690,"activeCount":63},[],{"trials":692,"activeCount":63},[693],{"nctId":694,"briefTitle":695,"status":122,"phases":696,"primaryCompletion":697,"completion":698,"start":699,"enrollment":700,"conditions":701,"interventions":703},"NCT01339065","The Effect of Ketamine on Production of Inflammatory Markers in Post Operative Patients in Mulago Hospital",[55],"2011-05","2011-06","2011-04",30,[702],"Post Operative Inflammatory Marker Levels",[681],{"trials":705,"activeCount":63},[],{"intervention":232,"totalTrials":59,"cells":707},{"EARLY_PHASE1":708,"PHASE1":710,"PHASE2":712,"PHASE3":714,"PHASE4":716,"NA":722},{"trials":709,"activeCount":63},[],{"trials":711,"activeCount":63},[],{"trials":713,"activeCount":63},[],{"trials":715,"activeCount":63},[],{"trials":717,"activeCount":63},[718],{"nctId":222,"briefTitle":223,"status":122,"phases":719,"completion":225,"start":226,"enrollment":227,"conditions":720,"interventions":721},[55],[229],[231,232],{"trials":723,"activeCount":63},[],{"intervention":725,"totalTrials":103,"cells":726},"darunavir",{"EARLY_PHASE1":727,"PHASE1":729,"PHASE2":731,"PHASE3":746,"PHASE4":765,"NA":767},{"trials":728,"activeCount":63},[],{"trials":730,"activeCount":63},[],{"trials":732,"activeCount":63},[733],{"nctId":734,"briefTitle":735,"status":122,"phases":736,"primaryCompletion":737,"completion":738,"start":739,"enrollment":740,"conditions":741,"interventions":743},"NCT03589040","Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant",[53],"2019-06","2020-06","2018-09-25",60,[15,742],"Contraception",[744,745,725],"Etonogestrel 68Mg Implant","rilpivirine",{"trials":747,"activeCount":63},[748],{"nctId":749,"briefTitle":750,"status":122,"phases":751,"primaryCompletion":752,"completion":753,"start":754,"enrollment":755,"conditions":756,"interventions":758},"NCT03988452","Nucleosides And Darunavir\u002FDolutegravir In Africa",[54],"2020-09-30","2021-09-30","2019-07-30",465,[757],"Human Immunodeficiency Virus",[759,760,761,762,763,764],"Darunavir","Ritonavir","Dolutegravir","Zidovudine","Tenofovir","Lamivudine",{"trials":766,"activeCount":63},[],{"trials":768,"activeCount":63},[],{"intervention":770,"totalTrials":59,"cells":771},"Mannitol",{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":776,"PHASE3":778,"PHASE4":790,"NA":792},{"trials":773,"activeCount":63},[],{"trials":775,"activeCount":63},[],{"trials":777,"activeCount":63},[],{"trials":779,"activeCount":63},[780],{"nctId":781,"briefTitle":782,"status":122,"phases":783,"completion":784,"start":785,"enrollment":786,"conditions":787,"interventions":789},"NCT00113854","Mannitol as Adjunct Therapy for Childhood Cerebral Malaria",[54],"2005-05","2004-10",156,[788],"Cerebral Malaria",[770],{"trials":791,"activeCount":63},[],{"trials":793,"activeCount":63},[],{"intervention":795,"totalTrials":59,"cells":796},"Amoxicillin",{"EARLY_PHASE1":797,"PHASE1":799,"PHASE2":801,"PHASE3":803,"PHASE4":818,"NA":820},{"trials":798,"activeCount":63},[],{"trials":800,"activeCount":63},[],{"trials":802,"activeCount":63},[],{"trials":804,"activeCount":63},[805],{"nctId":806,"briefTitle":807,"status":251,"phases":808,"primaryCompletion":809,"completion":809,"start":810,"enrollment":811,"conditions":812,"interventions":814},"NCT00933049","Cotrimoxazole Versus Amoxicillin in the Treatment of Community Acquired Pneumonia in Children Aged 2-59 Months",[54],"2008-01","2007-07",505,[813],"Childhood Pneumonia",[795,815,816,817],"Cotrimoxazole","Amoxicillin placebo","Cotrimoxazole placebo",{"trials":819,"activeCount":63},[],{"trials":821,"activeCount":63},[],{"intervention":815,"totalTrials":59,"cells":823},{"EARLY_PHASE1":824,"PHASE1":826,"PHASE2":828,"PHASE3":830,"PHASE4":836,"NA":838},{"trials":825,"activeCount":63},[],{"trials":827,"activeCount":63},[],{"trials":829,"activeCount":63},[],{"trials":831,"activeCount":63},[832],{"nctId":806,"briefTitle":807,"status":251,"phases":833,"primaryCompletion":809,"completion":809,"start":810,"enrollment":811,"conditions":834,"interventions":835},[54],[813],[795,815,816,817],{"trials":837,"activeCount":63},[],{"trials":839,"activeCount":63},[],{"intervention":816,"totalTrials":59,"cells":841},{"EARLY_PHASE1":842,"PHASE1":844,"PHASE2":846,"PHASE3":848,"PHASE4":854,"NA":856},{"trials":843,"activeCount":63},[],{"trials":845,"activeCount":63},[],{"trials":847,"activeCount":63},[],{"trials":849,"activeCount":63},[850],{"nctId":806,"briefTitle":807,"status":251,"phases":851,"primaryCompletion":809,"completion":809,"start":810,"enrollment":811,"conditions":852,"interventions":853},[54],[813],[795,815,816,817],{"trials":855,"activeCount":63},[],{"trials":857,"activeCount":63},[],{"intervention":817,"totalTrials":59,"cells":859},{"EARLY_PHASE1":860,"PHASE1":862,"PHASE2":864,"PHASE3":866,"PHASE4":872,"NA":874},{"trials":861,"activeCount":63},[],{"trials":863,"activeCount":63},[],{"trials":865,"activeCount":63},[],{"trials":867,"activeCount":63},[868],{"nctId":806,"briefTitle":807,"status":251,"phases":869,"primaryCompletion":809,"completion":809,"start":810,"enrollment":811,"conditions":870,"interventions":871},[54],[813],[795,815,816,817],{"trials":873,"activeCount":63},[],{"trials":875,"activeCount":63},[],{"intervention":877,"totalTrials":59,"cells":878},"ready-to-use therapeutic food",{"EARLY_PHASE1":879,"PHASE1":881,"PHASE2":883,"PHASE3":885,"PHASE4":896,"NA":898},{"trials":880,"activeCount":63},[],{"trials":882,"activeCount":63},[],{"trials":884,"activeCount":63},[],{"trials":886,"activeCount":63},[887],{"nctId":888,"briefTitle":889,"status":122,"phases":890,"completion":891,"start":785,"enrollment":892,"conditions":893,"interventions":895},"NCT00131417","Ready to Use Therapeutic Food in the Rehabilitation of Severely Malnourished Children",[54],"2005-02",128,[894],"Malnutrition",[877],{"trials":897,"activeCount":63},[],{"trials":899,"activeCount":63},[],{"intervention":901,"totalTrials":59,"cells":902},"Four monthly IPT with dihydroartemisinin Piperaquine",{"EARLY_PHASE1":903,"PHASE1":905,"PHASE2":907,"PHASE3":909,"PHASE4":921,"NA":923},{"trials":904,"activeCount":63},[],{"trials":906,"activeCount":63},[],{"trials":908,"activeCount":63},[],{"trials":910,"activeCount":63},[911],{"nctId":912,"briefTitle":913,"status":251,"phases":914,"primaryCompletion":915,"completion":915,"start":916,"enrollment":917,"conditions":918,"interventions":919},"NCT01231880","School Based Malaria Control in Ugandan Schoolchildren",[54],"2012-09","2011-02",740,[21],[901,920],"Monthly IPT using DP",{"trials":922,"activeCount":63},[],{"trials":924,"activeCount":63},[],{"intervention":920,"totalTrials":59,"cells":926},{"EARLY_PHASE1":927,"PHASE1":929,"PHASE2":931,"PHASE3":933,"PHASE4":939,"NA":941},{"trials":928,"activeCount":63},[],{"trials":930,"activeCount":63},[],{"trials":932,"activeCount":63},[],{"trials":934,"activeCount":63},[935],{"nctId":912,"briefTitle":913,"status":251,"phases":936,"primaryCompletion":915,"completion":915,"start":916,"enrollment":917,"conditions":937,"interventions":938},[54],[21],[901,920],{"trials":940,"activeCount":63},[],{"trials":942,"activeCount":63},[],{"intervention":944,"totalTrials":59,"cells":945},"Ceftriaxone Sodium",{"EARLY_PHASE1":946,"PHASE1":948,"PHASE2":950,"PHASE3":952,"PHASE4":966,"NA":968},{"trials":947,"activeCount":63},[],{"trials":949,"activeCount":63},[],{"trials":951,"activeCount":63},[],{"trials":953,"activeCount":63},[954],{"nctId":955,"briefTitle":956,"status":122,"phases":957,"primaryCompletion":958,"completion":958,"start":959,"enrollment":960,"conditions":961,"interventions":963},"NCT05051163","Strategies to Reduce Mortality Among HIV-infected and HIV-exposed Children Admitted With Severe Acute Malnutrition",[53,54],"2024-06-14","2021-06-14",300,[31,962],"Malnutrition, Child",[944,964,965],"Ampicillin","Gentamicin",{"trials":967,"activeCount":63},[],{"trials":969,"activeCount":63},[],{"intervention":964,"totalTrials":59,"cells":971},{"EARLY_PHASE1":972,"PHASE1":974,"PHASE2":976,"PHASE3":978,"PHASE4":984,"NA":986},{"trials":973,"activeCount":63},[],{"trials":975,"activeCount":63},[],{"trials":977,"activeCount":63},[],{"trials":979,"activeCount":63},[980],{"nctId":955,"briefTitle":956,"status":122,"phases":981,"primaryCompletion":958,"completion":958,"start":959,"enrollment":960,"conditions":982,"interventions":983},[53,54],[31,962],[944,964,965],{"trials":985,"activeCount":63},[],{"trials":987,"activeCount":63},[],{"intervention":965,"totalTrials":59,"cells":989},{"EARLY_PHASE1":990,"PHASE1":992,"PHASE2":994,"PHASE3":996,"PHASE4":1002,"NA":1004},{"trials":991,"activeCount":63},[],{"trials":993,"activeCount":63},[],{"trials":995,"activeCount":63},[],{"trials":997,"activeCount":63},[998],{"nctId":955,"briefTitle":956,"status":122,"phases":999,"primaryCompletion":958,"completion":958,"start":959,"enrollment":960,"conditions":1000,"interventions":1001},[53,54],[31,962],[944,964,965],{"trials":1003,"activeCount":63},[],{"trials":1005,"activeCount":63},[],{"intervention":1007,"totalTrials":59,"cells":1008},"Radiotherapy plus metronidazole",{"EARLY_PHASE1":1009,"PHASE1":1011,"PHASE2":1013,"PHASE3":1015,"PHASE4":1026,"NA":1028},{"trials":1010,"activeCount":63},[],{"trials":1012,"activeCount":63},[],{"trials":1014,"activeCount":63},[],{"trials":1016,"activeCount":63},[1017],{"nctId":1018,"briefTitle":1019,"status":251,"phases":1020,"primaryCompletion":1021,"completion":1021,"start":253,"enrollment":1022,"conditions":1023,"interventions":1025},"NCT01937650","Radiotherapy + Metronidazole vs Radiotherapy Alone In Improving Treatment Outcomes in Advanced Cervical Cancer in Uganda",[53,54],"2010-04",38,[1024],"Cervix Carcinoma",[1007],{"trials":1027,"activeCount":63},[],{"trials":1029,"activeCount":63},[],{"intervention":1031,"totalTrials":59,"cells":1032},"Intrarectal quinine",{"EARLY_PHASE1":1033,"PHASE1":1035,"PHASE2":1037,"PHASE3":1039,"PHASE4":1050,"NA":1052},{"trials":1034,"activeCount":63},[],{"trials":1036,"activeCount":63},[],{"trials":1038,"activeCount":63},[],{"trials":1040,"activeCount":63},[1041],{"nctId":1042,"briefTitle":1043,"status":122,"phases":1044,"completion":1045,"start":1046,"enrollment":1047,"conditions":1048,"interventions":1049},"NCT00124267","Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria",[54],"2004-01","2003-09",108,[788],[1031],{"trials":1051,"activeCount":63},[],{"trials":1053,"activeCount":63},[],{"intervention":1055,"totalTrials":59,"cells":1056},"IPT with Dihydroartemisinin Piperaquine",{"EARLY_PHASE1":1057,"PHASE1":1059,"PHASE2":1061,"PHASE3":1063,"PHASE4":1075,"NA":1077},{"trials":1058,"activeCount":63},[],{"trials":1060,"activeCount":63},[],{"trials":1062,"activeCount":63},[],{"trials":1064,"activeCount":63},[1065],{"nctId":1066,"briefTitle":1067,"status":122,"phases":1068,"primaryCompletion":1069,"completion":1070,"start":1071,"enrollment":1072,"conditions":1073,"interventions":1074},"NCT04660110","Household-level Impact of IPT of Malaria in Schoolchildren",[54],"2021-06-03","2021-06-30","2021-01-28",1500,[21],[1055],{"trials":1076,"activeCount":63},[],{"trials":1078,"activeCount":63},[],{"intervention":1080,"totalTrials":59,"cells":1081},"3-dayIVM 200 mcg\u002Fkg\u002Fday\u002F14-day 75mgASA\u002Fday + standard of care",{"EARLY_PHASE1":1082,"PHASE1":1084,"PHASE2":1086,"PHASE3":1088,"PHASE4":1098,"NA":1100},{"trials":1083,"activeCount":63},[],{"trials":1085,"activeCount":63},[],{"trials":1087,"activeCount":63},[],{"trials":1089,"activeCount":63},[1090],{"nctId":1091,"briefTitle":1092,"status":122,"phases":1093,"primaryCompletion":1070,"completion":753,"start":1094,"enrollment":1095,"conditions":1096,"interventions":1097},"NCT04768179","Safety & Efficacy of Low Dose Aspirin \u002F Ivermectin Combination Therapy for Treatment of Covid-19 Patients",[53,54],"2021-02-19",490,[33],[1080],{"trials":1099,"activeCount":63},[],{"trials":1101,"activeCount":63},[],{"intervention":1103,"totalTrials":59,"cells":1104},"100% Oxygen",{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1111,"PHASE4":1126,"NA":1128},{"trials":1106,"activeCount":63},[],{"trials":1108,"activeCount":63},[],{"trials":1110,"activeCount":63},[],{"trials":1112,"activeCount":63},[1113],{"nctId":1114,"briefTitle":1115,"status":122,"phases":1116,"primaryCompletion":1117,"completion":1118,"start":1119,"enrollment":1120,"conditions":1121,"interventions":1124},"NCT04043299","Effect of Intrapartum Oxygen Administration on Fetal and Early Neonatal Outcomes",[54],"2020-08-30","2020-10-30","2020-03-16",1108,[1122,1123],"Fetal Distress","Birth Asphyxia",[1103,1125],"21% oxygen",{"trials":1127,"activeCount":63},[],{"trials":1129,"activeCount":63},[],{"intervention":1125,"totalTrials":59,"cells":1131},{"EARLY_PHASE1":1132,"PHASE1":1134,"PHASE2":1136,"PHASE3":1138,"PHASE4":1144,"NA":1146},{"trials":1133,"activeCount":63},[],{"trials":1135,"activeCount":63},[],{"trials":1137,"activeCount":63},[],{"trials":1139,"activeCount":63},[1140],{"nctId":1114,"briefTitle":1115,"status":122,"phases":1141,"primaryCompletion":1117,"completion":1118,"start":1119,"enrollment":1120,"conditions":1142,"interventions":1143},[54],[1122,1123],[1103,1125],{"trials":1145,"activeCount":63},[],{"trials":1147,"activeCount":63},[],{"intervention":760,"totalTrials":59,"cells":1149},{"EARLY_PHASE1":1150,"PHASE1":1152,"PHASE2":1154,"PHASE3":1156,"PHASE4":1162,"NA":1164},{"trials":1151,"activeCount":63},[],{"trials":1153,"activeCount":63},[],{"trials":1155,"activeCount":63},[],{"trials":1157,"activeCount":63},[1158],{"nctId":749,"briefTitle":750,"status":122,"phases":1159,"primaryCompletion":752,"completion":753,"start":754,"enrollment":755,"conditions":1160,"interventions":1161},[54],[757],[759,760,761,762,763,764],{"trials":1163,"activeCount":63},[],{"trials":1165,"activeCount":63},[],{"intervention":761,"totalTrials":59,"cells":1167},{"EARLY_PHASE1":1168,"PHASE1":1170,"PHASE2":1172,"PHASE3":1174,"PHASE4":1180,"NA":1182},{"trials":1169,"activeCount":63},[],{"trials":1171,"activeCount":63},[],{"trials":1173,"activeCount":63},[],{"trials":1175,"activeCount":63},[1176],{"nctId":749,"briefTitle":750,"status":122,"phases":1177,"primaryCompletion":752,"completion":753,"start":754,"enrollment":755,"conditions":1178,"interventions":1179},[54],[757],[759,760,761,762,763,764],{"trials":1181,"activeCount":63},[],{"trials":1183,"activeCount":63},[],{"intervention":762,"totalTrials":59,"cells":1185},{"EARLY_PHASE1":1186,"PHASE1":1188,"PHASE2":1190,"PHASE3":1192,"PHASE4":1198,"NA":1200},{"trials":1187,"activeCount":63},[],{"trials":1189,"activeCount":63},[],{"trials":1191,"activeCount":63},[],{"trials":1193,"activeCount":63},[1194],{"nctId":749,"briefTitle":750,"status":122,"phases":1195,"primaryCompletion":752,"completion":753,"start":754,"enrollment":755,"conditions":1196,"interventions":1197},[54],[757],[759,760,761,762,763,764],{"trials":1199,"activeCount":63},[],{"trials":1201,"activeCount":63},[],{"intervention":763,"totalTrials":59,"cells":1203},{"EARLY_PHASE1":1204,"PHASE1":1206,"PHASE2":1208,"PHASE3":1210,"PHASE4":1216,"NA":1218},{"trials":1205,"activeCount":63},[],{"trials":1207,"activeCount":63},[],{"trials":1209,"activeCount":63},[],{"trials":1211,"activeCount":63},[1212],{"nctId":749,"briefTitle":750,"status":122,"phases":1213,"primaryCompletion":752,"completion":753,"start":754,"enrollment":755,"conditions":1214,"interventions":1215},[54],[757],[759,760,761,762,763,764],{"trials":1217,"activeCount":63},[],{"trials":1219,"activeCount":63},[],{"intervention":764,"totalTrials":59,"cells":1221},{"EARLY_PHASE1":1222,"PHASE1":1224,"PHASE2":1226,"PHASE3":1228,"PHASE4":1234,"NA":1236},{"trials":1223,"activeCount":63},[],{"trials":1225,"activeCount":63},[],{"trials":1227,"activeCount":63},[],{"trials":1229,"activeCount":63},[1230],{"nctId":749,"briefTitle":750,"status":122,"phases":1231,"primaryCompletion":752,"completion":753,"start":754,"enrollment":755,"conditions":1232,"interventions":1233},[54],[757],[759,760,761,762,763,764],{"trials":1235,"activeCount":63},[],{"trials":1237,"activeCount":63},[],{"intervention":1239,"totalTrials":59,"cells":1240},"Inhaled corticosteroid",{"EARLY_PHASE1":1241,"PHASE1":1243,"PHASE2":1245,"PHASE3":1247,"PHASE4":1261,"NA":1263},{"trials":1242,"activeCount":63},[],{"trials":1244,"activeCount":63},[],{"trials":1246,"activeCount":63},[],{"trials":1248,"activeCount":63},[1249],{"nctId":1250,"briefTitle":1251,"status":251,"phases":1252,"primaryCompletion":1253,"completion":1253,"start":1254,"enrollment":1255,"conditions":1256,"interventions":1260},"NCT01868113","Inhaled Corticosteroids in U-5 Children With Acute Respiratory Infection in Uganda: A Randomised Trial",[54],"2014-01","2012-12",1010,[1257,1258,1259],"Bacterial Pneumonia","Viral Pneumonia","Acute Asthma",[1239],{"trials":1262,"activeCount":63},[],{"trials":1264,"activeCount":63},[],{"intervention":1266,"totalTrials":59,"cells":1267},"Zinc acetate",{"EARLY_PHASE1":1268,"PHASE1":1270,"PHASE2":1272,"PHASE3":1274,"PHASE4":1286,"NA":1288},{"trials":1269,"activeCount":63},[],{"trials":1271,"activeCount":63},[],{"trials":1273,"activeCount":63},[],{"trials":1275,"activeCount":63},[1276],{"nctId":1277,"briefTitle":1278,"status":251,"phases":1279,"primaryCompletion":1280,"completion":1280,"start":1281,"enrollment":1282,"conditions":1283,"interventions":1285},"NCT00373100","The Efficacy of Zinc as Adjunct Therapy in the Treatment of Severe Pneumonia in Children",[54],"2007-03","2006-09",328,[1284],"Pneumonia",[1266],{"trials":1287,"activeCount":63},[],{"trials":1289,"activeCount":63},[],{"intervention":1291,"totalTrials":59,"cells":1292},"sulfadoxine pyrimethamine",{"EARLY_PHASE1":1293,"PHASE1":1295,"PHASE2":1297,"PHASE3":1299,"PHASE4":1311,"NA":1313},{"trials":1294,"activeCount":63},[],{"trials":1296,"activeCount":63},[],{"trials":1298,"activeCount":63},[],{"trials":1300,"activeCount":63},[1301],{"nctId":1302,"briefTitle":1303,"status":251,"phases":1304,"primaryCompletion":1305,"completion":1305,"start":1306,"enrollment":1307,"conditions":1308,"interventions":1310},"NCT00399074","Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prevention in Children With Sickle Cell Anemia",[54],"2007-02","2006-10",220,[1309,21],"Sickle Cell Anemia",[1291],{"trials":1312,"activeCount":63},[],{"trials":1314,"activeCount":63},[],{"intervention":1316,"totalTrials":59,"cells":1317},"Carvedilol",{"EARLY_PHASE1":1318,"PHASE1":1320,"PHASE2":1322,"PHASE3":1324,"PHASE4":1336,"NA":1338},{"trials":1319,"activeCount":63},[],{"trials":1321,"activeCount":63},[],{"trials":1323,"activeCount":63},[],{"trials":1325,"activeCount":63},[1326],{"nctId":1327,"briefTitle":1328,"status":122,"phases":1329,"primaryCompletion":1330,"completion":1330,"start":1331,"enrollment":1332,"conditions":1333,"interventions":1335},"NCT03542058","Detecting and Treating Subclinical Anthracycline Therapy Related Cardiac Dysfunction in Low Income Country.",[54],"2021-06","2018-06",50,[1334],"Chemotherapy Related Cardiac Dysfunction",[1316],{"trials":1337,"activeCount":63},[],{"trials":1339,"activeCount":63},[],{"intervention":1341,"totalTrials":59,"cells":1342},"Ketamine-Midazolam",{"EARLY_PHASE1":1343,"PHASE1":1345,"PHASE2":1347,"PHASE3":1349,"PHASE4":1363,"NA":1365},{"trials":1344,"activeCount":63},[],{"trials":1346,"activeCount":63},[],{"trials":1348,"activeCount":63},[],{"trials":1350,"activeCount":63},[1351],{"nctId":1352,"briefTitle":1353,"status":1354,"phases":1355,"primaryCompletion":1356,"completion":754,"start":1357,"enrollment":1358,"conditions":1359,"interventions":1361},"NCT03407404","Comparing Clinical Outcomes Between Ketamine-midazolam and Morphine-midazolam for Continous Sedation in ICU Patients.","TERMINATED",[53,54],"2019-06-15","2017-10-22",124,[1360],"Critical Illness",[1341,1362],"Morphine -Midazolam",{"trials":1364,"activeCount":63},[],{"trials":1366,"activeCount":63},[],{"intervention":1362,"totalTrials":59,"cells":1368},{"EARLY_PHASE1":1369,"PHASE1":1371,"PHASE2":1373,"PHASE3":1375,"PHASE4":1381,"NA":1383},{"trials":1370,"activeCount":63},[],{"trials":1372,"activeCount":63},[],{"trials":1374,"activeCount":63},[],{"trials":1376,"activeCount":63},[1377],{"nctId":1352,"briefTitle":1353,"status":1354,"phases":1378,"primaryCompletion":1356,"completion":754,"start":1357,"enrollment":1358,"conditions":1379,"interventions":1380},[53,54],[1360],[1341,1362],{"trials":1382,"activeCount":63},[],{"trials":1384,"activeCount":63},[],{"intervention":1386,"totalTrials":59,"cells":1387},"BCG at birth",{"EARLY_PHASE1":1388,"PHASE1":1390,"PHASE2":1392,"PHASE3":1394,"PHASE4":1408,"NA":1410},{"trials":1389,"activeCount":63},[],{"trials":1391,"activeCount":63},[],{"trials":1393,"activeCount":63},[],{"trials":1395,"activeCount":63},[1396],{"nctId":1397,"briefTitle":1398,"status":251,"phases":1399,"primaryCompletion":1400,"completion":1400,"start":672,"enrollment":1401,"conditions":1402,"interventions":1406},"NCT02606526","Early Versus Late BCG Vaccination in HIV-1 Exposed Infants in Uganda in Uganda",[54],"2024-06-21",4500,[1403,676,1404,1405],"Severe Illness","Diarrhoea","Lower Respiratory Infection",[1386,1407],"Control arm: Delayed BCG",{"trials":1409,"activeCount":63},[],{"trials":1411,"activeCount":63},[],{"intervention":1407,"totalTrials":59,"cells":1413},{"EARLY_PHASE1":1414,"PHASE1":1416,"PHASE2":1418,"PHASE3":1420,"PHASE4":1426,"NA":1428},{"trials":1415,"activeCount":63},[],{"trials":1417,"activeCount":63},[],{"trials":1419,"activeCount":63},[],{"trials":1421,"activeCount":63},[1422],{"nctId":1397,"briefTitle":1398,"status":251,"phases":1423,"primaryCompletion":1400,"completion":1400,"start":672,"enrollment":1401,"conditions":1424,"interventions":1425},[54],[1403,676,1404,1405],[1386,1407],{"trials":1427,"activeCount":63},[],{"trials":1429,"activeCount":63},[],{"intervention":1431,"totalTrials":59,"cells":1432},"Influenza vaccine",{"EARLY_PHASE1":1433,"PHASE1":1435,"PHASE2":1437,"PHASE3":1439,"PHASE4":1452,"NA":1454},{"trials":1434,"activeCount":63},[],{"trials":1436,"activeCount":63},[],{"trials":1438,"activeCount":63},[],{"trials":1440,"activeCount":63},[1441],{"nctId":1442,"briefTitle":1443,"status":122,"phases":1444,"primaryCompletion":1445,"completion":1446,"start":1447,"enrollment":1448,"conditions":1449,"interventions":1451},"NCT03666806","Preventing Stroke Triggers in Children With Sickle Cell Anaemia in Mulago Hospital, Kampala (PREST ): a Randomized Control Trial",[53,54],"2019-09","2019-12","2018-08-22",150,[1450],"Preventing Stroke in Sickle Cell Anaemia",[1431],{"trials":1453,"activeCount":63},[],{"trials":1455,"activeCount":63},[],{"intervention":1457,"totalTrials":59,"cells":1458},"Misoprostol Pfizer Brand",{"EARLY_PHASE1":1459,"PHASE1":1461,"PHASE2":1463,"PHASE3":1465,"PHASE4":1478,"NA":1480},{"trials":1460,"activeCount":63},[],{"trials":1462,"activeCount":63},[],{"trials":1464,"activeCount":63},[],{"trials":1466,"activeCount":63},[1467],{"nctId":1468,"briefTitle":1469,"status":122,"phases":1470,"primaryCompletion":1471,"completion":1472,"start":1473,"enrollment":1474,"conditions":1475,"interventions":1477},"NCT03509168","The Efficacy and Safety of Preoperative Misoprostol in Blood-loss Reduction During Myomectomy.",[53,54],"2018-05-30","2018-06-03","2018-01-10",46,[1476],"Uterine Fibroid",[1457],{"trials":1479,"activeCount":63},[],{"trials":1481,"activeCount":63},[],{"intervention":1483,"totalTrials":59,"cells":1484},"ceftriaxone",{"EARLY_PHASE1":1485,"PHASE1":1487,"PHASE2":1489,"PHASE3":1491,"PHASE4":1500,"NA":1502},{"trials":1486,"activeCount":63},[],{"trials":1488,"activeCount":63},[],{"trials":1490,"activeCount":63},[],{"trials":1492,"activeCount":63},[1493],{"nctId":1494,"briefTitle":1495,"status":251,"phases":1496,"primaryCompletion":1280,"completion":1280,"start":1281,"enrollment":1497,"conditions":1498,"interventions":1499},"NCT00372541","Ceftriaxone Versus Chloramphenicol for Treatment of Severe Pneumonia in Children",[54],348,[1284],[1483],{"trials":1501,"activeCount":63},[],{"trials":1503,"activeCount":63},[],{"intervention":1505,"totalTrials":59,"cells":1506},"ART, Atorvastatin",{"EARLY_PHASE1":1507,"PHASE1":1509,"PHASE2":1511,"PHASE3":1513,"PHASE4":1528,"NA":1530},{"trials":1508,"activeCount":63},[],{"trials":1510,"activeCount":63},[],{"trials":1512,"activeCount":63},[],{"trials":1514,"activeCount":63},[1515],{"nctId":1516,"briefTitle":1517,"status":122,"phases":1518,"primaryCompletion":1519,"completion":448,"start":1520,"enrollment":1521,"conditions":1522,"interventions":1524},"NCT03037372","Statin Adjunct Therapy Among ART-treated Adults in Sub-Saharan Africa: Atorvastatin and Rosuvastatin Equivalence Trial",[54],"2022-06-30","2017-06-01",320,[1523],"HIV Infection",[1505,1525,1526,1527],"ART, Rosuvastatin","ART, No statin","Healthy-HIV-negative",{"trials":1529,"activeCount":63},[],{"trials":1531,"activeCount":63},[],{"intervention":1525,"totalTrials":59,"cells":1533},{"EARLY_PHASE1":1534,"PHASE1":1536,"PHASE2":1538,"PHASE3":1540,"PHASE4":1546,"NA":1548},{"trials":1535,"activeCount":63},[],{"trials":1537,"activeCount":63},[],{"trials":1539,"activeCount":63},[],{"trials":1541,"activeCount":63},[1542],{"nctId":1516,"briefTitle":1517,"status":122,"phases":1543,"primaryCompletion":1519,"completion":448,"start":1520,"enrollment":1521,"conditions":1544,"interventions":1545},[54],[1523],[1505,1525,1526,1527],{"trials":1547,"activeCount":63},[],{"trials":1549,"activeCount":63},[],{"intervention":1526,"totalTrials":59,"cells":1551},{"EARLY_PHASE1":1552,"PHASE1":1554,"PHASE2":1556,"PHASE3":1558,"PHASE4":1564,"NA":1566},{"trials":1553,"activeCount":63},[],{"trials":1555,"activeCount":63},[],{"trials":1557,"activeCount":63},[],{"trials":1559,"activeCount":63},[1560],{"nctId":1516,"briefTitle":1517,"status":122,"phases":1561,"primaryCompletion":1519,"completion":448,"start":1520,"enrollment":1521,"conditions":1562,"interventions":1563},[54],[1523],[1505,1525,1526,1527],{"trials":1565,"activeCount":63},[],{"trials":1567,"activeCount":63},[],{"intervention":1527,"totalTrials":59,"cells":1569},{"EARLY_PHASE1":1570,"PHASE1":1572,"PHASE2":1574,"PHASE3":1576,"PHASE4":1582,"NA":1584},{"trials":1571,"activeCount":63},[],{"trials":1573,"activeCount":63},[],{"trials":1575,"activeCount":63},[],{"trials":1577,"activeCount":63},[1578],{"nctId":1516,"briefTitle":1517,"status":122,"phases":1579,"primaryCompletion":1519,"completion":448,"start":1520,"enrollment":1521,"conditions":1580,"interventions":1581},[54],[1523],[1505,1525,1526,1527],{"trials":1583,"activeCount":63},[],{"trials":1585,"activeCount":63},[],{"intervention":745,"totalTrials":103,"cells":1587},{"EARLY_PHASE1":1588,"PHASE1":1590,"PHASE2":1592,"PHASE3":1608,"PHASE4":1610,"NA":1612},{"trials":1589,"activeCount":63},[],{"trials":1591,"activeCount":63},[],{"trials":1593,"activeCount":63},[1594,1598],{"nctId":734,"briefTitle":735,"status":122,"phases":1595,"primaryCompletion":737,"completion":738,"start":739,"enrollment":740,"conditions":1596,"interventions":1597},[53],[15,742],[744,745,725],{"nctId":1599,"briefTitle":1600,"status":122,"phases":1601,"primaryCompletion":737,"completion":738,"start":1602,"enrollment":740,"conditions":1603,"interventions":1604},"NCT03589027","Darunavir and Rilpivirine Interactions With Levonorgestrel Implant",[53],"2018-08-07",[31,742],[1605,1606,1607],"Levonorgestrel two rod sub-dermal implant","Rilpivirine","Darunavir+Ritonavir",{"trials":1609,"activeCount":63},[],{"trials":1611,"activeCount":63},[],{"trials":1613,"activeCount":63},[],{"intervention":744,"totalTrials":59,"cells":1615},{"EARLY_PHASE1":1616,"PHASE1":1618,"PHASE2":1620,"PHASE3":1626,"PHASE4":1628,"NA":1630},{"trials":1617,"activeCount":63},[],{"trials":1619,"activeCount":63},[],{"trials":1621,"activeCount":63},[1622],{"nctId":734,"briefTitle":735,"status":122,"phases":1623,"primaryCompletion":737,"completion":738,"start":739,"enrollment":740,"conditions":1624,"interventions":1625},[53],[15,742],[744,745,725],{"trials":1627,"activeCount":63},[],{"trials":1629,"activeCount":63},[],{"trials":1631,"activeCount":63},[],{"intervention":1633,"totalTrials":59,"cells":1634},"Praziquantel",{"EARLY_PHASE1":1635,"PHASE1":1637,"PHASE2":1639,"PHASE3":1650,"PHASE4":1652,"NA":1654},{"trials":1636,"activeCount":63},[],{"trials":1638,"activeCount":63},[],{"trials":1640,"activeCount":63},[1641],{"nctId":1642,"briefTitle":1643,"status":251,"phases":1644,"primaryCompletion":1645,"completion":1645,"start":1254,"enrollment":1646,"conditions":1647,"interventions":1649},"NCT01901484","Schistosoma Mansoni Morbidity in Children Aged 1-5 Years",[53],"2014-02",800,[1648],"Intestinal Schistosomiasis",[1633],{"trials":1651,"activeCount":63},[],{"trials":1653,"activeCount":63},[],{"trials":1655,"activeCount":63},[],{"intervention":1657,"totalTrials":59,"cells":1658},"Isoniazid",{"EARLY_PHASE1":1659,"PHASE1":1661,"PHASE2":1663,"PHASE3":1674,"PHASE4":1676,"NA":1678},{"trials":1660,"activeCount":63},[],{"trials":1662,"activeCount":63},[],{"trials":1664,"activeCount":63},[1665],{"nctId":1666,"briefTitle":1667,"status":122,"phases":1668,"primaryCompletion":1669,"completion":1519,"start":1670,"enrollment":1671,"conditions":1672,"interventions":1673},"NCT05124678","Pharmacogenetics-guided Isoniazid Dosing in TB-HIV",[53],"2022-03-30","2021-12-07",40,[24],[1657],{"trials":1675,"activeCount":63},[],{"trials":1677,"activeCount":63},[],{"trials":1679,"activeCount":63},[],{"intervention":1681,"totalTrials":59,"cells":1682},"Hydroxychloroquine",{"EARLY_PHASE1":1683,"PHASE1":1685,"PHASE2":1687,"PHASE3":1699,"PHASE4":1701,"NA":1703},{"trials":1684,"activeCount":63},[],{"trials":1686,"activeCount":63},[],{"trials":1688,"activeCount":63},[1689],{"nctId":1690,"briefTitle":1691,"status":122,"phases":1692,"primaryCompletion":1693,"completion":1694,"start":1695,"enrollment":1696,"conditions":1697,"interventions":1698},"NCT04860284","Hydroxychloroquine for Treatment of Non-Severe COVID-19",[53],"2021-02-09","2021-12-01","2020-09-18",105,[33],[1681],{"trials":1700,"activeCount":63},[],{"trials":1702,"activeCount":63},[],{"trials":1704,"activeCount":63},[],{"intervention":1605,"totalTrials":59,"cells":1706},{"EARLY_PHASE1":1707,"PHASE1":1709,"PHASE2":1711,"PHASE3":1717,"PHASE4":1719,"NA":1721},{"trials":1708,"activeCount":63},[],{"trials":1710,"activeCount":63},[],{"trials":1712,"activeCount":63},[1713],{"nctId":1599,"briefTitle":1600,"status":122,"phases":1714,"primaryCompletion":737,"completion":738,"start":1602,"enrollment":740,"conditions":1715,"interventions":1716},[53],[31,742],[1605,1606,1607],{"trials":1718,"activeCount":63},[],{"trials":1720,"activeCount":63},[],{"trials":1722,"activeCount":63},[],{"intervention":1607,"totalTrials":59,"cells":1724},{"EARLY_PHASE1":1725,"PHASE1":1727,"PHASE2":1729,"PHASE3":1735,"PHASE4":1737,"NA":1739},{"trials":1726,"activeCount":63},[],{"trials":1728,"activeCount":63},[],{"trials":1730,"activeCount":63},[1731],{"nctId":1599,"briefTitle":1600,"status":122,"phases":1732,"primaryCompletion":737,"completion":738,"start":1602,"enrollment":740,"conditions":1733,"interventions":1734},[53],[31,742],[1605,1606,1607],{"trials":1736,"activeCount":63},[],{"trials":1738,"activeCount":63},[],{"trials":1740,"activeCount":63},[],{"intervention":1742,"totalTrials":59,"cells":1743},"TAZCOV",{"EARLY_PHASE1":1744,"PHASE1":1746,"PHASE2":1748,"PHASE3":1760,"PHASE4":1762,"NA":1764},{"trials":1745,"activeCount":63},[],{"trials":1747,"activeCount":63},[],{"trials":1749,"activeCount":63},[1750],{"nctId":1751,"briefTitle":1752,"status":122,"phases":1753,"primaryCompletion":214,"completion":214,"start":1754,"enrollment":1755,"conditions":1756,"interventions":1758},"NCT05897203","Clinical Trial of Natural Therapeutics for COVID-19 and Other Acute Respiratory Viral Infections",[53],"2023-03-03",510,[1757],"Acute Respiratory Infection",[1742,1759],"Vidicine",{"trials":1761,"activeCount":63},[],{"trials":1763,"activeCount":63},[],{"trials":1765,"activeCount":63},[],{"intervention":1759,"totalTrials":59,"cells":1767},{"EARLY_PHASE1":1768,"PHASE1":1770,"PHASE2":1772,"PHASE3":1778,"PHASE4":1780,"NA":1782},{"trials":1769,"activeCount":63},[],{"trials":1771,"activeCount":63},[],{"trials":1773,"activeCount":63},[1774],{"nctId":1751,"briefTitle":1752,"status":122,"phases":1775,"primaryCompletion":214,"completion":214,"start":1754,"enrollment":1755,"conditions":1776,"interventions":1777},[53],[1757],[1742,1759],{"trials":1779,"activeCount":63},[],{"trials":1781,"activeCount":63},[],{"trials":1783,"activeCount":63},[],{"intervention":1785,"totalTrials":59,"cells":1786},"Rifampin 300 Mg Oral",{"EARLY_PHASE1":1787,"PHASE1":1789,"PHASE2":1791,"PHASE3":1803,"PHASE4":1805,"NA":1807},{"trials":1788,"activeCount":63},[],{"trials":1790,"activeCount":63},[],{"trials":1792,"activeCount":63},[1793],{"nctId":1794,"briefTitle":1795,"status":251,"phases":1796,"primaryCompletion":1797,"completion":1798,"start":1799,"enrollment":1800,"conditions":1801,"interventions":1802},"NCT03982277","Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy",[53],"2021-03-16","2021-07-23","2019-04-30",130,[24],[1785],{"trials":1804,"activeCount":63},[],{"trials":1806,"activeCount":63},[],{"trials":1808,"activeCount":63},[],{"intervention":1810,"totalTrials":59,"cells":1811},"Remdesivir",{"EARLY_PHASE1":1812,"PHASE1":1814,"PHASE2":1816,"PHASE3":1829,"PHASE4":1831,"NA":1833},{"trials":1813,"activeCount":63},[],{"trials":1815,"activeCount":63},[],{"trials":1817,"activeCount":63},[1818],{"nctId":1819,"briefTitle":1820,"status":251,"phases":1821,"primaryCompletion":1822,"completion":1823,"start":1824,"enrollment":1825,"conditions":1826,"interventions":1828},"NCT04385719","Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy",[53],"2021-07-02","2021-07-16","2021-05-05",24,[1827,26],"Ebola",[1810],{"trials":1830,"activeCount":63},[],{"trials":1832,"activeCount":63},[],{"trials":1834,"activeCount":63},[],{"intervention":1836,"totalTrials":59,"cells":1837},"COVIDEX",{"EARLY_PHASE1":1838,"PHASE1":1840,"PHASE2":1842,"PHASE3":1854,"PHASE4":1856,"NA":1858},{"trials":1839,"activeCount":63},[],{"trials":1841,"activeCount":63},[],{"trials":1843,"activeCount":63},[1844],{"nctId":1845,"briefTitle":1846,"status":122,"phases":1847,"primaryCompletion":1848,"completion":448,"start":1849,"enrollment":1850,"conditions":1851,"interventions":1853},"NCT05228626","Safety and Efficacy of COVIDEX™ Therapy in Management of Adult COVID-19 Patients in Uganda.",[53],"2022-11-30","2022-03-01",584,[1852],"COVID-19",[1836],{"trials":1855,"activeCount":63},[],{"trials":1857,"activeCount":63},[],{"trials":1859,"activeCount":63},[],{"intervention":1861,"totalTrials":59,"cells":1862},"Autologous adipose derived stem cells",{"EARLY_PHASE1":1863,"PHASE1":1865,"PHASE2":1867,"PHASE3":1881,"PHASE4":1883,"NA":1885},{"trials":1864,"activeCount":63},[],{"trials":1866,"activeCount":63},[],{"trials":1868,"activeCount":63},[1869],{"nctId":1870,"briefTitle":1871,"status":251,"phases":1872,"primaryCompletion":1873,"completion":1873,"start":1874,"enrollment":22,"conditions":1875,"interventions":1880},"NCT04553159","Autologous Adipose Derived Stem Cells Transplantation in the Treatment of Keloids.",[53],"2021-06-16","2021-03-01",[1876,1877,1878,1879],"Keloid","Autologus Adipose Derived Stem Cells","Feasibility","Safety",[1861],{"trials":1882,"activeCount":63},[],{"trials":1884,"activeCount":63},[],{"trials":1886,"activeCount":63},[],{"intervention":1888,"totalTrials":59,"cells":1889},"Triamcinolone Acetonide 40Mg\u002FMl Inj,Susp_#1",{"EARLY_PHASE1":1890,"PHASE1":1892,"PHASE2":1894,"PHASE3":1906,"PHASE4":1908,"NA":1910},{"trials":1891,"activeCount":63},[],{"trials":1893,"activeCount":63},[],{"trials":1895,"activeCount":63},[1896],{"nctId":1897,"briefTitle":1898,"status":122,"phases":1899,"primaryCompletion":1900,"completion":1901,"start":1902,"enrollment":700,"conditions":1903,"interventions":1905},"NCT04391621","Efficacy of Adipose Derived Stromal Vascular Fraction in the Treatment of Keloids",[53],"2021-12-30","2023-12-31","2021-05-01",[1904,1876],"Adipose Derived Stem Cells",[1888],{"trials":1907,"activeCount":63},[],{"trials":1909,"activeCount":63},[],{"trials":1911,"activeCount":63},[],{"intervention":1913,"totalTrials":59,"cells":1914},"Lorazepam",{"EARLY_PHASE1":1915,"PHASE1":1917,"PHASE2":1929,"PHASE3":1931,"PHASE4":1933,"NA":1935},{"trials":1916,"activeCount":63},[],{"trials":1918,"activeCount":63},[1919],{"nctId":1920,"briefTitle":1921,"status":251,"phases":1922,"primaryCompletion":1923,"completion":1923,"start":1923,"enrollment":1924,"conditions":1925,"interventions":1928},"NCT02462109","Catatonia in Nodding Syndrome and Lorazepam Treatment",[52],"2013-03",16,[1926,1927],"Catatonia","Nodding Syndrome",[1913],{"trials":1930,"activeCount":63},[],{"trials":1932,"activeCount":63},[],{"trials":1934,"activeCount":63},[],{"trials":1936,"activeCount":63},[],{"intervention":1938,"totalTrials":103,"cells":1939},"dexamethasone",{"EARLY_PHASE1":1940,"PHASE1":1942,"PHASE2":1944,"PHASE3":1956,"PHASE4":1958,"NA":1960},{"trials":1941,"activeCount":63},[],{"trials":1943,"activeCount":63},[],{"trials":1945,"activeCount":63},[1946],{"nctId":1947,"briefTitle":1948,"status":251,"phases":1949,"primaryCompletion":1950,"completion":1950,"start":1951,"enrollment":1952,"conditions":1953,"interventions":1955},"NCT02372812","Analgesic Effects Of Dexamethasone; Its Use To Reduce Post Operative Pain Scores",[53],"2015-02","2014-07",173,[1954],"Pain",[1938],{"trials":1957,"activeCount":63},[],{"trials":1959,"activeCount":63},[],{"trials":1961,"activeCount":63},[1962],{"nctId":1963,"briefTitle":1964,"status":251,"phases":1965,"primaryCompletion":1966,"completion":1966,"start":1967,"enrollment":1968,"conditions":1969,"interventions":1971},"NCT01028547","Antiemetic Efficacy and Safety of Dexamethasone in Obstetric Surgical Patients",[56],"2010-03","2010-01",250,[1970],"Postoperative Nausea and Vomiting",[1938],{"intervention":1973,"totalTrials":59,"cells":1974},"Lamivudine-Tenofovir 300 Mg-300 Mg Oral",{"EARLY_PHASE1":1975,"PHASE1":1977,"PHASE2":1979,"PHASE3":1981,"PHASE4":1983,"NA":1985},{"trials":1976,"activeCount":63},[],{"trials":1978,"activeCount":63},[],{"trials":1980,"activeCount":63},[],{"trials":1982,"activeCount":63},[],{"trials":1984,"activeCount":63},[],{"trials":1986,"activeCount":63},[1987],{"nctId":1988,"briefTitle":1989,"status":251,"phases":1990,"primaryCompletion":1991,"completion":1991,"start":1992,"enrollment":1993,"conditions":1994,"interventions":1997},"NCT04867798","Transgender Men and HIV in Uganda: PrEP Uptake and Persistence",[],"2023-04-30","2021-09-16",75,[15,1995,28,1996],"Sexually Transmitted Infections","Transgender Men",[1973],{"intervention":1999,"totalTrials":59,"cells":2000},"Albendazole 400 mg, given 6 monthly",{"EARLY_PHASE1":2001,"PHASE1":2003,"PHASE2":2005,"PHASE3":2007,"PHASE4":2009,"NA":2011},{"trials":2002,"activeCount":63},[],{"trials":2004,"activeCount":63},[],{"trials":2006,"activeCount":63},[],{"trials":2008,"activeCount":63},[],{"trials":2010,"activeCount":63},[],{"trials":2012,"activeCount":63},[2013],{"nctId":2014,"briefTitle":2015,"status":251,"phases":2016,"completion":2017,"start":2018,"enrollment":2019,"conditions":2020,"interventions":2022},"NCT00344669","Effect of Mass Deworming on Child Growth",[56],"2003-11","2000-08",10000,[2021],"Low Weight for Age in Preschool Children",[1999],{"intervention":2024,"totalTrials":59,"cells":2025},"intravenous artesunate",{"EARLY_PHASE1":2026,"PHASE1":2028,"PHASE2":2030,"PHASE3":2032,"PHASE4":2034,"NA":2036},{"trials":2027,"activeCount":63},[],{"trials":2029,"activeCount":63},[],{"trials":2031,"activeCount":63},[],{"trials":2033,"activeCount":63},[],{"trials":2035,"activeCount":63},[],{"trials":2037,"activeCount":63},[2038],{"nctId":2039,"briefTitle":2040,"status":122,"phases":2041,"primaryCompletion":2042,"completion":2043,"start":2044,"enrollment":362,"conditions":2045,"interventions":2047},"NCT01122134","Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate for Severe Malaria Treatment",[],"2010-08","2010-09","2010-05",[2046],"Severe Malaria",[2024],{"intervention":2049,"totalTrials":59,"cells":2050},"Antiretroviral treatment",{"EARLY_PHASE1":2051,"PHASE1":2053,"PHASE2":2055,"PHASE3":2057,"PHASE4":2059,"NA":2061},{"trials":2052,"activeCount":63},[],{"trials":2054,"activeCount":63},[],{"trials":2056,"activeCount":63},[],{"trials":2058,"activeCount":63},[],{"trials":2060,"activeCount":63},[],{"trials":2062,"activeCount":63},[2063],{"nctId":2064,"briefTitle":2065,"status":122,"phases":2066,"primaryCompletion":2067,"completion":2067,"start":2068,"enrollment":2069,"conditions":2070,"interventions":2073},"NCT04313699","Geriatric HIV Cohort in Sub Sahara Africa",[],"2023-06-30","2020-07-01",500,[18,2071,2072],"Non Communicable Diseases","Aging",[2049],{"intervention":2075,"totalTrials":59,"cells":2076},"COVID Convalescent Plasma",{"EARLY_PHASE1":2077,"PHASE1":2079,"PHASE2":2081,"PHASE3":2083,"PHASE4":2085,"NA":2087},{"trials":2078,"activeCount":63},[],{"trials":2080,"activeCount":63},[],{"trials":2082,"activeCount":63},[],{"trials":2084,"activeCount":63},[],{"trials":2086,"activeCount":63},[],{"trials":2088,"activeCount":63},[2089],{"nctId":2090,"briefTitle":2091,"status":251,"phases":2092,"primaryCompletion":2093,"completion":2093,"start":2094,"enrollment":2095,"conditions":2096,"interventions":2097},"NCT04542941","Assessment of Safety and Efficacy of CCP",[56],"2020-12-31","2020-06-16",136,[33],[2075],{"intervention":2099,"totalTrials":59,"cells":2100},"10% dextrose",{"EARLY_PHASE1":2101,"PHASE1":2103,"PHASE2":2105,"PHASE3":2107,"PHASE4":2109,"NA":2111},{"trials":2102,"activeCount":63},[],{"trials":2104,"activeCount":63},[],{"trials":2106,"activeCount":63},[],{"trials":2108,"activeCount":63},[],{"trials":2110,"activeCount":63},[],{"trials":2112,"activeCount":63},[2113],{"nctId":2114,"briefTitle":2115,"status":1354,"phases":2116,"primaryCompletion":2117,"completion":2117,"start":2118,"enrollment":2119,"conditions":2120,"interventions":2122},"NCT01688674","Dextrose Infusion by Burettes Versus Dextrose Boluses in Prevention of Neonatal Hypoglycemia",[56],"2012-04","2012-02",140,[2121],"Once a Preterm Developed Hypoglycemia, no More Blood Glucose Was Measured During the Study Period.",[2099],{"intervention":2124,"totalTrials":59,"cells":2125},"Blood transfusion",{"EARLY_PHASE1":2126,"PHASE1":2128,"PHASE2":2130,"PHASE3":2132,"PHASE4":2134,"NA":2136},{"trials":2127,"activeCount":63},[],{"trials":2129,"activeCount":63},[],{"trials":2131,"activeCount":63},[],{"trials":2133,"activeCount":63},[],{"trials":2135,"activeCount":63},[],{"trials":2137,"activeCount":63},[2138],{"nctId":2139,"briefTitle":2140,"status":251,"phases":2141,"primaryCompletion":2142,"completion":2143,"start":254,"enrollment":2144,"conditions":2145,"interventions":2147},"NCT01580111","Effect of Blood Storage Age on the Resolution of Lactic Acidosis in Children With Severe Malarial Anemia at Mulago Hospital",[56],"2011-08","2011-11",74,[2146],"Compare Blood Age for Transfusion",[2124],{"intervention":2149,"totalTrials":59,"cells":2150},"Integrated Next Steps Counseling with Real-Time Drug Level Feedback",{"EARLY_PHASE1":2151,"PHASE1":2153,"PHASE2":2155,"PHASE3":2157,"PHASE4":2159,"NA":2161},{"trials":2152,"activeCount":63},[],{"trials":2154,"activeCount":63},[],{"trials":2156,"activeCount":63},[],{"trials":2158,"activeCount":63},[],{"trials":2160,"activeCount":63},[],{"trials":2162,"activeCount":63},[2163],{"nctId":2164,"briefTitle":2165,"status":251,"phases":2166,"primaryCompletion":2167,"completion":2167,"start":2168,"enrollment":115,"conditions":2169,"interventions":2172},"NCT04491422","Same-Day PrEP Initiation and Sexual Health for Transgender Women",[56],"2023-07-05","2021-11-02",[15,28,2170,2171],"Transgender Women","Sexually Transmitted Diseases, Bacterial",[2149],{"intervention":2174,"totalTrials":59,"cells":2175},"Intrathecal morphine with fentanyl",{"EARLY_PHASE1":2176,"PHASE1":2178,"PHASE2":2180,"PHASE3":2182,"PHASE4":2184,"NA":2186},{"trials":2177,"activeCount":63},[],{"trials":2179,"activeCount":63},[],{"trials":2181,"activeCount":63},[],{"trials":2183,"activeCount":63},[],{"trials":2185,"activeCount":63},[],{"trials":2187,"activeCount":63},[2188],{"nctId":2189,"briefTitle":2190,"status":251,"phases":2191,"primaryCompletion":2192,"completion":2192,"start":1253,"enrollment":450,"conditions":2193,"interventions":2195},"NCT02498171","Labour Analgesia; Comparing a Combinations of Either Fentanyl or Bupivacaine With Intrathecal Morphine",[56],"2014-03",[2194],"Labor Pain",[2174,2196],"Intrathecal morphine with bupivacaine",{"intervention":2196,"totalTrials":59,"cells":2198},{"EARLY_PHASE1":2199,"PHASE1":2201,"PHASE2":2203,"PHASE3":2205,"PHASE4":2207,"NA":2209},{"trials":2200,"activeCount":63},[],{"trials":2202,"activeCount":63},[],{"trials":2204,"activeCount":63},[],{"trials":2206,"activeCount":63},[],{"trials":2208,"activeCount":63},[],{"trials":2210,"activeCount":63},[2211],{"nctId":2189,"briefTitle":2190,"status":251,"phases":2212,"primaryCompletion":2192,"completion":2192,"start":1253,"enrollment":450,"conditions":2213,"interventions":2214},[56],[2194],[2174,2196],{"intervention":2216,"totalTrials":59,"cells":2217},"0.9% Normal Saline",{"EARLY_PHASE1":2218,"PHASE1":2220,"PHASE2":2222,"PHASE3":2224,"PHASE4":2226,"NA":2228},{"trials":2219,"activeCount":63},[],{"trials":2221,"activeCount":63},[],{"trials":2223,"activeCount":63},[],{"trials":2225,"activeCount":63},[],{"trials":2227,"activeCount":63},[],{"trials":2229,"activeCount":63},[2230],{"nctId":2231,"briefTitle":2232,"status":251,"phases":2233,"primaryCompletion":2117,"completion":2234,"start":2235,"enrollment":2069,"conditions":2236,"interventions":2238},"NCT01585740","Ringer's Lactate Versus Normal Saline in Caesarean Section",[56],"2012-05","2011-09",[2237],"Normal Anion Gap Metabolic Acidosis",[2216,2239],"Ringer's Lactate",{"intervention":2239,"totalTrials":59,"cells":2241},{"EARLY_PHASE1":2242,"PHASE1":2244,"PHASE2":2246,"PHASE3":2248,"PHASE4":2250,"NA":2252},{"trials":2243,"activeCount":63},[],{"trials":2245,"activeCount":63},[],{"trials":2247,"activeCount":63},[],{"trials":2249,"activeCount":63},[],{"trials":2251,"activeCount":63},[],{"trials":2253,"activeCount":63},[2254],{"nctId":2231,"briefTitle":2232,"status":251,"phases":2255,"primaryCompletion":2117,"completion":2234,"start":2235,"enrollment":2069,"conditions":2256,"interventions":2257},[56],[2237],[2216,2239]]